Diabetic Kidney Disease Market Report 2026

The diabetic kidney disease market size has grown strongly in recent years. It will grow from $2.8 billion in 2025 to $2.96 billion in 2026 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to high prevalence of diabetes-related kidney damage, late-stage disease diagnosis, limited early screening adoption, reliance on dialysis at advanced stages, rising hospitalization rates.

The diabetic kidney disease market size is expected to see strong growth in the next few years. It will grow to $3.76 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to advancements in renal protective drugs, increasing early diagnosis initiatives, growing chronic kidney disease burden, expansion of specialty nephrology care, focus on personalized treatment strategies. Major trends in the forecast period include growing adoption of early renal screening, increased use of renoprotective drug therapies, expansion of combination treatment approaches, rising focus on disease progression delay, integration of multidisciplinary care models.

The increasing prevalence of chronic kidney disease is expected to drive the growth of the diabetic kidney disease market. Chronic kidney disease (CKD) is a long-term condition marked by the gradual loss of kidney function, leading to complications such as hypertension, anemia, and bone disorders. Managing chronic kidney disease requires extensive diagnostic and therapeutic interventions, which in turn supports the expansion of the diabetic kidney disease market. For instance, in June 2023, according to Kidney Research UK, a UK-based charity, chronic kidney disease affects approximately 7.2 million people in the United Kingdom, representing more than 10% of the population. Of these, around 3.25 million individuals are in the advanced stages of the disease, while nearly 3.9 million are in the early stages, which are often asymptomatic and untreated. Projections indicate that the total number of people living with chronic kidney disease in the UK could rise to 7.61 million by 2033. Therefore, the growing prevalence of chronic kidney disease is fueling the growth of the diabetic kidney disease market.

Major companies operating in the diabetic kidney disease market are increasingly focusing on integrating advanced technologies such as artificial intelligence (AI)-enabled prognostic platforms to improve early risk identification, personalized disease management, and long-term patient outcomes. AI-enabled prognostic platforms are diagnostic solutions that combine blood-based biomarker data with machine-learning algorithms to predict the risk of progressive kidney function decline. These platforms enable features such as risk score generation, patient stratification, and early clinical intervention planning. For instance, in June 2023, Renalytix plc, a UK-based diagnostics company, received U.S. Food and Drug Administration (FDA) De Novo marketing authorization for KidneyIntelX.dkd, an AI-driven prognostic platform designed to evaluate the risk of significant kidney function deterioration in adults with type 2 diabetes and early-stage chronic kidney disease. The platform incorporates biomarker-based machine-learning algorithms, cloud-enabled workflow integration, and stratified risk reporting, supporting improved clinical decision-making and proactive patient care.

In January 2023, AstraZeneca, a UK-based biotechnology and pharmaceutical company, acquired CinCor Pharma Inc. for an undisclosed amount. This acquisition is intended to strengthen AstraZeneca’s cardiorenal portfolio through the addition of CinCor’s lead candidate, baxdrostat (CIN-107), an aldosterone synthase inhibitor developed for blood pressure reduction in treatment-resistant hypertension. CinCor Pharma Inc. is a US-based biopharmaceutical company focused on developing therapies for kidney disease management.

Major companies operating in the diabetic kidney disease market are AstraZeneca plc, Pfizer Inc., Novartis AG, Bayer AG, Sanofi SA, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Fresenius SE & Co. KGaA, F. Hoffmann-La Roche AG, Abbott Laboratories, Reata Pharmaceuticals Inc., Merck & Co., Mitsubishi Tanabe Pharma Corporation, Johnson & Johnson pvt. Ltd., Eli Lilly and Company, GlaxoSmithKline plc, AbbVie Inc., Boehringer Ingelheim International GmbH, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited.

North America was the largest region in the diabetic kidney disease market in 2025. The regions covered in the diabetic kidney disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diabetic kidney disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the diabetic kidney disease market by increasing costs of imported diagnostic reagents, renal drugs, and dialysis-related equipment. Hospitals and dialysis centers in North America and Europe are most affected due to dependence on imported supplies, while Asia-Pacific faces higher equipment procurement costs. These tariffs raise treatment expenses. However, they also support domestic production of renal care drugs and localized manufacturing of dialysis equipment.

The diabetic kidney disease market research report is one of a series of new reports that provides diabetic kidney disease market statistics, including diabetic kidney disease industry global market size, regional shares, competitors with a diabetic kidney disease market share, detailed diabetic kidney disease market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic kidney disease industry. This diabetic kidney disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Diabetic kidney disease is a form of renal disorder caused by complications of diabetes that develops when prolonged high blood sugar levels damage the kidneys. Elevated blood glucose affects the blood vessels within the kidneys, gradually impairing their function and reducing their ability to filter waste effectively.

The main types of diabetic kidney disease are associated with type 1 diabetes and type 2 diabetes. Type 1 diabetes is a chronic autoimmune condition in which the pancreas produces little or no insulin, resulting in elevated blood glucose levels that damage nephrons and renal blood vessels and require daily insulin administration for blood sugar control. Treatment options include angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, antioxidant inflammation modulators, calcium channel blockers, and other therapies. These treatments are provided through healthcare settings such as hospitals, home care, specialty centers, and others.

The diabetic kidney disease market includes revenues earned by entities by providing diabetic kidney disease treatments for kidney stones, kidney infection, polycystic kidney disease, and kidney cysts. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.